ClinicalTrials.gg
RecruitingNCT07128394ELH-IVFUpdated Aug 19, 2025

Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment

An interventional study of Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle-Stimulating Hormone (rFSH) in Infertility, Female and Luteinizing Hormone (LH), sponsored by Nanjing University. Recruiting at 1 site in China. Open to female participants aged 20 Years to 37 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Nanjing University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Feb 2024, registered Aug 2025).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
590
Allocation
Randomized
Ages
20 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Infertility, Female with a site in China — 17 open to participants now, 20 under way, 1 of them phase 3. Infertility, Female · China.

Planned enrollment
11th of 51
590 · median 178
Started
2024
with 3 others
No phase
32 of 58
12 open now
Primary completion
2026-09
later than 13 of 19 live
Registered
54th of 58
by date
Lead sponsor
4 of 58
Nanjing University

Among the 58 studies in Infertility, Female with a site in China, this one is the 11th largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2024, is one of 32 with no phase, reaches primary completion later than 13 of the 19 other live ones, and was the 54th registered.

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

Browse Infertility, Female studies →

Open to participants now

17 of the 58 studies in Infertility, Female with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Infertility, Female studies recruiting now, 11 (13%) set no upper age limit and 77 (88%) stop at 75 or younger; 9 take children under 18; 29 take healthy volunteers.

This study: 20 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Infertility, Female with a site in China, or all of them as a file.
02

Study summary

This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.

Read the detailed description

Excessive suppression of luteinizing hormone (LH) during ovarian stimulation with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol has been associated with suboptimal follicular development, impaired oocyte maturation, and reduced embryo quality. LH plays a critical role in the final stages of folliculogenesis, steroidogenesis, and ovulation, and its deficiency during controlled ovarian hyperstimulation may adversely affect the developmental competence of oocytes.

This randomized controlled trial is designed to evaluate whether supplementation with exogenous LH can improve embryo quality in patients undergoing in vitro fertilization (IVF) with excessive LH suppression during a long GnRH-a protocol. Eligible participants are women meeting predefined hormonal suppression criteria prior to or during stimulation. Participants will be randomly assigned to receive either exogenous LH supplementation in addition to standard ovarian stimulation or standard care without LH supplementation.

The primary endpoint is the proportion of high-quality embryos obtained per cycle. Secondary endpoints include clinical pregnancy rate, implantation rate, live birth rate, and safety outcomes such as incidence of ovarian hyperstimulation syndrome (OHSS) and adverse events.

The study aims to provide high-quality evidence to guide the optimal management of patients with profound LH suppression during controlled ovarian stimulation. Findings from this trial may contribute to refining stimulation protocols and improving reproductive outcomes in assisted reproductive technology (ART).

03

Conditions studied

  • Infertility, Female
  • Luteinizing Hormone (LH)

Browse trials for

Keywords

  • Luteinizing Hormone
  • Long GnRH Agonist Protocol
  • Excessive LH Suppression
  • Controlled Ovarian Stimulation
  • In Vitro Fertilization
  • Embryo Quality
04

Who can participate

Ages eligible
20 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 20 to 37 years (inclusive). Diagnosed with infertility and undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment using the long-acting GnRH agonist protocol.

Serum luteinizing hormone (LH) level \<0.5 U/L after pituitary downregulation. Normal uterine cavity as confirmed by hysteroscopy, sonohysterography, or hysterosalpingography within 6 months.

Written provided prior to participation.

Exclusion criteria

Exclusion Criteria:

  • Polycystic ovary syndrome (PCOS). History of recurrent implantation failure (RIF). Presence of endometriosis or adenomyosis. History of ovarian surgery. Ovarian cysts ≥3 cm or with suspected . Poor ovarian reserve (antral follicle count \<5, anti-Müllerian hormone \<1.1 ng/mL, or baseline FSH >10 IU/L).

Chromosomal abnormalities in either partner. Systemic diseases such as uncontrolled hypertension, diabetes, thyroid disorders, or diseases.

to ovarian stimulation medications or pregnancy.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
590 participants (estimated)

Study arms

  • Experimental
    Recombinant LH Supplementation Group

    Participants receive controlled ovarian hyperstimulation (COH) using a long-acting GnRH agonist (triptorelin 3.75 mg) for pituitary downregulation, followed by recombinant FSH (rFSH) combined with recombinant LH (rLH) at a ratio of 2:1 starting on stimulation day. rLH administration continues throughout the stimulation phase, with gonadotropin doses adjusted based on follicular growth and hormone monitoring. Trigger is given when 2-3 leading follicles reach ≥18 mm, followed by oocyte retrieval, IVF/ICSI, and embryo quality assessment.

    Drug: Recombinant Luteinizing Hormone (rLH) · Drug: Recombinant Follicle-Stimulating Hormone (rFSH) · Drug: Gonadotropin-Releasing Hormone Agonist (GnRH-a)

  • Active comparator
    Conventional rFSH-Only Group

    Participants receive the same long-acting GnRH agonist downregulation and rFSH stimulation protocol as the experimental arm, but without rLH supplementation. Only rFSH is used during COH, with dose adjustments according to follicular development and hormone levels. Trigger, oocyte retrieval, IVF/ICSI, and embryo assessment follow the same procedures as in the experimental arm.

    Drug: Recombinant Follicle-Stimulating Hormone (rFSH) · Drug: Gonadotropin-Releasing Hormone Agonist (GnRH-a)

Interventions

  • DrugLuteinizing HormoneStudies of Luteinizing HormoneLuteinizing Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Recombinant LH administered subcutaneously in combination with recombinant FSH (rFSH) at a ratio of 2:1 starting on stimulation day, continued throughout controlled ovarian hyperstimulation. Dosage adjusted according to follicular growth and serum hormone levels.

    Also known as: lutropin alfa, Luveris

  • DrugFollitropin alfaStudies of Follitropin alfaFollitropin alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Recombinant FSH administered subcutaneously for controlled ovarian hyperstimulation after pituitary downregulation with a long-acting GnRH agonist. Dosage adjusted based on follicular development and hormone monitoring.

    Also known as: follitropin alfa, Gonal-F

  • DrugGonadotropin-releasing Hormone AnalogStudies of Gonadotropin-releasing Hormone AnalogGonadotropin-releasing Hormone Analog pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Long-acting GnRH agonist (3.75 mg) administered subcutaneously on menstrual cycle day 2-4 for pituitary downregulation before controlled ovarian hyperstimulation.

    Also known as: triptorelin, Diphereline

06

What researchers measure

Primary outcomes

  1. Proportion of cycles with no usable embryos

    The number of IVF/ICSI cycles with no transferable embryos divided by the total number of oocyte retrieval cycles, evaluated based on embryo morphology and grading on Day 3 or Day 5-6 after fertilization.

    Time frame: 7 days after oocyte retrieval

Secondary outcomes

  1. Number of high-quality Day 3 embryos

    Count of embryos meeting morphological criteria for high quality on Day 3 after fertilization, as determined by standard embryology scoring.

    Time frame: 7 days after oocyte retrieval

  2. Total gonadotropin dose used

    Cumulative dose (IU) of gonadotropins administered from stimulation start to trigger day.

    Time frame: At the end of ovarian stimulation (average 8-12 days)

  3. Duration of gonadotropin stimulation

    Number of days from gonadotropin initiation to trigger day.

    Time frame: At the end of ovarian stimulation (average 8-12 days)

  4. Number of oocytes retrieved

    Total number of oocytes collected during transvaginal ultrasound-guided oocyte retrieval.

    Time frame: At oocyte retrieval (36-38 hours after trigger)

  5. Clinical pregnancy rate

    Proportion of embryo transfer cycles resulting in at least one intrauterine gestational sac with fetal heartbeat, confirmed by transvaginal ultrasound.

    Time frame: 30 days after embryo transfer

  6. Early miscarriage rate

    Proportion of clinical pregnancies ending in miscarriage before 12 completed weeks of gestation.

    Time frame: Within 12 weeks of gestation

  7. Live birth rate

    Proportion of embryo transfer cycles resulting in the delivery of at least one live-born infant.

    Time frame: At delivery (up to 1 year after embryo transfer)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yazici Yilmaz F, Gorkemli H, Colakoglu MC, Aktan M, Gezginc K. The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation. Gynecol Endocrinol. 2015 Feb;31(2):141-4. doi: 10.3109/09513590.2014.965675. Epub 2014 Sep 19. PubMed 25237892 ↗
  • Tesarik J, Mendoza C. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence. Hum Reprod. 2002 Dec;17(12):3129-37. doi: 10.1093/humrep/17.12.3129. PubMed 12456612 ↗
  • Wu KK, Papp AC, Manner CE, Hall ER. Interaction between lymphocytes and platelets in the synthesis of prostacyclin. J Clin Invest. 1987 Jun;79(6):1601-6. doi: 10.1172/JCI112995. PubMed 3108319 ↗
  • Kan O, Simsir C, Atabekoglu CS, Sonmezer M. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome. Gynecol Endocrinol. 2019 Oct;35(10):869-872. doi: 10.1080/09513590.2019.1600667. Epub 2019 Apr 11. PubMed 30973022 ↗
  • Propst AM, Hill MJ, Bates GW, Palumbo M, Van Horne AK, Retzloff MG. Low-dose human chorionic gonadotropin may improve in vitro fertilization cycle outcomes in patients with low luteinizing hormone levels after gonadotropin-releasing hormone antagonist administration. Fertil Steril. 2011 Oct;96(4):898-904. doi: 10.1016/j.fertnstert.2011.06.069. Epub 2011 Aug 11. PubMed 21839437 ↗
  • Tayyar AT, Kahraman S. Comparison between cycles of the same patients when using recombinant luteinizing hormone + recombinant follicle stimulating hormone (rFSH), human menopausal gonadotropin + rFSH and rFSH only. Arch Med Sci. 2019 May;15(3):673-679. doi: 10.5114/aoms.2017.72408. Epub 2018 Jan 8. PubMed 31110533 ↗
  • Fleming R, Rehka P, Deshpande N, Jamieson ME, Yates RW, Lyall H. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum Reprod. 2000 Jul;15(7):1440-5. doi: 10.1093/humrep/15.7.1440. PubMed 10875848 ↗
  • Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000 May;15(5):1003-8. doi: 10.1093/humrep/15.5.1003. PubMed 10783342 ↗
  • Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Outlook: who needs LH in ovarian stimulation? Reprod Biomed Online. 2006 May;12(5):599-607. doi: 10.1016/s1472-6483(10)61186-8. PubMed 16790105 ↗
  • Li F, Ye T, Kong H, Li J, Hu L, Jin H, Su Y, Li G. Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria. Aging (Albany NY). 2020 May 29;12(10):9354-9364. doi: 10.18632/aging.103210. Epub 2020 May 29. PubMed 32470947 ↗

Individual participant data

Plan to share: No — Individual participant data will not be shared due to concerns regarding patient privacy, confidentiality, and compliance with local regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Sep 2026, 31 months after the start.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 31 months is above that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 19, 2025
StartActual
Feb 1, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07128394
Lead sponsor
Nanjing University
Responsible party
Li-jun Ding (Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing University) — Principal investigator
First posted
Aug 19, 2025
Start date
Feb 1, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Aug 19, 2025

Study contacts

Yue Jiang, PhD
Contact
jiangyue85@163.com
+8613814122872
Hui Zhang, PhD
Contact
hellozhanghui@sina.cn
+8618262637731
慧 Jiang, PhD
principal investigator · Nanjing Drum Tower Hospital: Nanjing University Medical School Affiliated Nanjing Drum Tower Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luteinizing Hormone

Start the discussion